VETOQUINOL Corporate brochure 2007 (year 2007)

Description of a leading company Vétoquinol, a family-owned, independent veterinary pharmaceutical company, is exclusively devoted to animal health. Its business is voluntarily equally focussed on companion animals and livestock. Already established in the French market, 78% of the Group’s consolidated turnover (233.4 million euros in 2007) is now generated outside France. Since 2000, the Group has doubled the number of employees to 1300 in 2007, working in Research & Development, manufacturing, marketing and sales. This “small business” in France, ranked 12 th in the world, now manufactures and distributes 700 medicinal and nutraceutical products in almost 100 countries throughout Europe, North America and Asia. It has subsidiaries in 18 countries and a network of 110 third-party distributors. This expansion, +10.3%, i.e. 3 rd in the world market in 2007, is due to the judicious combination of external growth and the development of market leading products, as well as clearly focussing on: • three main therapeutic areas: infectious diseases, pain and inflammation and cardiology-nephrology, • three territories (Europe, North America and Asia), • three species (companion animals, cattle and pigs). Activity report 2007 / Focus #01 75 years in the service of animal health 1933 • First quinoline-based veterinary product, Vétoquinol, developed by Joseph Frechin, Doctor of Pharmacology 1962 • Founding of Vétoquinol SA, devoted to animal health • Arrival of Étienne Frechin, son of Joseph Frechin, current President 1980 • Research & Development centre opened 1987 • Tolfedine ® , first marketed (anti-inflammatory) 1995 • European launch of Marbocyl ® (anti-infective) 1999 • Acquisition of J.Webster in Canada - 40 employees 2001 • Acquisition of Swiss-based group Chassot and subsidiaries in Europe (401 employees) 2002 • Evsco and Tomlyn ranges bought from IGI Inc in the USA • Prilium ® launched (canine cardiology) 2003 • New premises at Lure double the amount of space for Research & Development 2004 • Choice to concentrate exclusively on the development of curative products • Sales office opened in Shanghai, China, for Asia-South Pacific 2005 • Launch of Clavaseptin ® (anti-infective) 2006 • Lure manufacturing site modernised and production capacity increased • Acquisition of Semyung Vet in South Korea and Vet Solutions in the USA • Listed on Paris stock market • Launch of Marbocyl ® S (antibiotic), Dolpac ® (antiparasitic) and Flexadin (chondroprotective agent) 2007 • Subsidiary established in Portugal • Launch of Alfaxan ® (anaesthetic) 2008 • Development unit established in Canada • Acquisition of Viavet in Scandinavia • Launch of Vetprofen ® (anti-inflammatory)